Chairman and CEO Richard Pops told attendees at the 2026 TD Cowen Healthcare Conference that the company entered 2026 with ...

One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Alkermes’ investigational ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...

— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested — — ALKS ...

Recently, Alkermes refocused on neuroscience, and now it’s dealing with stabilizing revenues from core products like Lybalvi, Vivitrol, Aristada, and Vumerity. However, the main growth driver going ...

Analyst Uy Ear of Mizuho Securities maintained a Buy rating on Alkermes (ALKS – Research Report), retaining the price target of $35.00. Uy Ear has given his Buy rating due to a combination of factors ...

Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2). Narcolepsy type ...

— Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist — In a separate oral ...

On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion. The deal ...

Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...

Alkermes plc (Nasdaq: ALKS) (Alkermes) today announced that Richard Pops will retire from his role as Chief Executive Officer (CEO), effective July 31, 2026. Alkermes’ Board of Directors (the Board) ...